"CYNA is now well funded, NASDAQ-listed and liquid; it isdefinitely among my better ideas as of today." (7/8/15) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Jason Napodano More >
"BCLI has what looks to be a safe and potentially effective treatment for delaying disease progression in patients with ALS." (7/8/15) BrainStorm Cell Therapeutics Inc. - The Life Sciences Report Interview with Jason Napodano More >
"If results from RVX's Phase 3 program are positive, the stock could have a significant revaluation to much higher levels." (7/8/15) Resverlogix Corp. - The Life Sciences Report Interview with Jason Napodano More >
The Life Sciences Report Biotech Watchlist Portfolio Tracker
It has been a boom year for biotechs, and most of the companies on The Life Sciences Report's Biotech Watchlist 2013 have risen with the proverbial tide. The Watchlist companies were selected by industry experts based on a variety of factors, including sound science, good management, therapy area and catalysts keyed to the drug development process. We have been tracking the companies throughout the year: With our new Portfolio Tracker, it is now easy for Life Science Report readers to do the same.
October 2013 Biotech Watchlist Update
January 2013 Biotech Watchlist
April 2013 Biotech Watchlist Update
How Are They Doing? Update on the Progress of Expert Picks
The Approval Process in Action (infographic)
The chart below shows stock prices for the 17 companies on the 2013 Biotech Watchlist. The heavy green line shows the average gain/loss of the portfolio as a whole. Portfolio average change year-to-date is [loading].
About These Individual Charts
The Yahoo finance charts provided below are updated in real time and show stock prices for each company for the year to date. Time spans for catalysts identified by Biotech Watchlist analysts are lighted in green.
"INO has a broad platform that includes an IL-12 DNA vaccine and other DNA vaccines for both cancer and infectious diseases." (6/24/15) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with George Zavoico More >
"The intriguing component of SNSS' VALOR study is a nice survival benefit seen in patients 60 years and older." (6/17/15) Sunesis Pharmaceuticals Inc. - The Life Sciences Report Interview with Joe Pantginis More >
"Following the 12-week endpoint, CANF's CF101 continued accumulation and the responses have become much better." (6/17/15) Can-Fite BioPharma Ltd. - The Life Sciences Report Interview with Joe Pantginis More >